Quantitative chemical proteomics profiling differentiates erlotinib from gefitinib in EGFR wild-type non-small cell lung carcinoma cell lines

Molecular Cancer Therapeutics

Volumn 12, Issue 4, 2013, Pages 520-529

  Augustin, Angélique ^a   Lamerz, Jens ^b   Meistermann, Hélène ^a   Golling, Sabrina ^a   Scheiblich, Stefan ^c   Hermann, Johannes C ^d   Duchateau Nguyen, Guillemette ^b   Tzouros, Manuel ^a   Avila, David W ^a   Langen, Hanno ^a   Essioux, Laurent ^b   Klughammer, Barbara ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c ROCHE INNOVATION CENTER MUNICH   (Germany)

^d HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB;

ALPHA PARVIN GENE; ARTICLE; BETA PARVIN GENE; BINDING SITE; CATENIN BETA GENE; CATENIN DELTA; COMPLEX FORMATION; DRUG PROTEIN BINDING; DRUG SENSITIVITY; E CADHERIN GENE; E47 BASIC LOOP HELIX GENE; EPIMORPHIN GENE; EPITHELIAL MESENCHYMAL TRANSITION; FIBRONECTIN GENE; GENE; ILK GENE; INTEGRIN LINKED KINASE GENE; LEF 1 GENE; LUNG NON SMALL CELL CANCER; METASTASIS ASSOCIATED PROTEIN 3 GENE; ONCOGENE MYC; PINCH 1 GENE; PINCH 2 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PROTEOMICS; SIGNAL TRANSDUCTION; SLUG GENE; SNAIL GENE; TWIST GENE; VIMENTIN GENE; WILD TYPE; Y BOX BINDING PROTEIN 1 GENE; ZEB GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATE; BINDING SITES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMANS; LIM DOMAIN PROTEINS; LUNG NEOPLASMS; MEMBRANE PROTEINS; MICROFILAMENT PROTEINS; MOLECULAR CONFORMATION; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; PROTEOMICS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84876463914     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0880     Document Type: Article

References (44)

1. McDermott U, Settleman J. Personalized cancertherapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J Clin Oncol 2009;27:5650-9.
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32. (Pubitemid 41058344)
3. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhàsz E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9.
4. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
5. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372: 1809-18.
6. Paz-Ares L, Soulieres D, Melezínek I, Moecks J, Keil L, Mok T, et al. Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med 2010;14: 51-69.
7. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004;22:777-84. (Pubitemid 41103588)
8. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-94. (Pubitemid 41103589)
9. Rix U, Superti-Furga G. Target profiling of small molecules by chemical proteomics. Nat Chem Biol 2009;5:616-24.
10. Bantscheff M, Scholten A, Heck AJ. Revealing promiscuous drug-target interactions by chemical proteomics. Drug Discov Today 2009;14:1021-9.
11. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010;29: 4741-51.
12. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005;11:8686-98. (Pubitemid 43005918)
13. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005;65:9455-62. (Pubitemid 41508014)
14. Cabodi S, Del Pilar Camacho-Leal M, Di Stefano P, Defilippi P. Integrin signalling adaptors: not only figurants in the cancer story. Nat Rev Cancer 2010;10:858-70.
15. Oloumi A, McPhee T, Dedhar S. Regulation of E-cadherin expression and beta-catenin/Tcf transcriptional activity by the integrin-linked kinase. Biochim Biophys Acta 2004;1691:1-15. (Pubitemid 38410945)
16. Li Y, Dai C, Wu C, Liu Y. PINCH-1 promotes tubular epithelial-to- mesenchymal transition by interacting with integrin-linked kinase. J Am Soc Nephrol 2007;18:2534-43. (Pubitemid 47378870)
17. Serrano I, McDonald PC, Lock FE, Dedhar S. Role of the integrin-linked kinase (ILK)/Rictor complex in TGFbeta-1-induced epithelial-mesen-chymal transition (EMT). Oncogene 2012;32:50-60.
18. Tan EH, Ramlau R, Pluzanska A, Kuo HP, Reck M, Milanowski J, et al.A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. Ann Oncol 2010;21:217-22.
19. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, et al. Cellular targets of gefitinib. Cancer Res 2005;65:379-82.
20. Schnur RC, Arnold LD. Qinazoline derivatives. International patent application publication number WO1996/30347.
21. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996;68:850-8.
22. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The protein data bank. Nucleic Acids Res 2000;28:235-42. (Pubitemid 30047768)
23. Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002;277:46265-72. (Pubitemid 35417619)
24. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007;11:217-27. (Pubitemid 46349842)
25. Fukuda K, Gupta S, Chen K, Wu C, Qin J. The pseudoactive site of ILK is essential for its binding to alpha-Parvin and localization to focal adhesions. Mol Cell 2009;36:819-30.
26. The PyMOL Molecular Graphics System V, Schrodinger, LLC.
27. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
28. Holder D, Raubertas RF, Pikounis VB, Svetnik V, Soper K. Statistical analysis of high density oligonucleotide arrays: a SAFER approach. In: Proceedings of the ASA Annual Meeting 2001; Atlanta, GA; 2001.
29. Bretz F, Hothorn LA. Testing dose-response relationships with a priori unknown, possibly nonmonotone shapes. J Biopharm Stat 2001;11: 193-207. (Pubitemid 33062688)
30. Thomson S, Petti F, Sujka-Kwok I, Epstein D, Haley JD. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis 2008;25:843-54.
31. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007;25:1035-44. (Pubitemid 47517638)
32. Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009;23: 477-85.
33. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-32.
34. Patricelli MP, Nomanbhoy TK, Wu J, Brown H, Zhou D, Zhang J, et al. In situ kinase profiling reveals functionally relevant properties of native kinases. Chem Biol 2011;18:699-710.
35. Muller K, Faeh C, Diederich F. Fluorine in pharmaceuticals: looking beyond intuition. Science 2007;317:1881-6. (Pubitemid 47509426)
36. Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, et al. Mol Cancer Ther 2004;3:465-72.
37. Kook EH, Kim YM, Kim HT, Koh JS, Choi YJ, Rho JK, et al. Prognostic value of E-cadherin expression in non-small cell lung cancer treated with gefitinib. Oncol Res 2010;18:445-51.
38. Yu J, Shi R, Zhang D, Wang E, Qiu X. Expression of integrin-linked kinase in lung squamous cell carcinoma and adenocarcinoma: correlation with E-cadherin expression, tumor microvessel density and clinical outcome. Virchows Arch 2011;458:99-107.
39. Li Y, Yang J, Dai C, Wu C, Liu Y. Role for integrin-linked kinase in mediating tubular epithelial to mesenchymal transition and renal interstitial fibrogenesis. J Clin Invest 2003;112:503-16. (Pubitemid 38056335)
40. Somasiri A, Howarth A, Goswami D, Dedhar S, Roskelley CD. Over-expression of the integrin-linked kinase mesenchymally transforms mammary epithelial cells. J Cell Sci 2001;114:1125-36. (Pubitemid 32288526)
41. Fukuda T, Chen K, Shi X, Wu C. PINCH-1 is an obligate partner of integrin-linked kinase (ILK) functioning in cell shape modulation, motil-ity, and survival. J Biol Chem 2003;278:51324-33. (Pubitemid 38020371)
42. Okamura M, Yamaji S, Nagashima Y, Nishikawa M, Yoshimoto N, Kido Y, et al. Prognostic value of integrin beta1-ILK-pAkt signaling pathway in non-small cell lung cancer. Hum Pathol 2007;38:1081-91. (Pubitemid 46899154)
43. Wang-Rodriguez J, Dreilinger AD, Alsharabi GM, Rearden A. The signaling adapter protein PINCH is up-regulated in the stroma of common cancers, notably at invasive edges. Cancer 2002;95: 1387-95. (Pubitemid 35013075)
44. Takanami I. Increased expression of integrin-linked kinase is associated with shorter survival in non-small cell lung cancer. BMC Cancer 2005;5:1.